Cdh5(PAC)-CreERT2 Mouse

Random Transgenic

Cdh5(PAC)-CreERT2 Random Transgenic Mouse Model

C57BL/6 Background

  • Model #
  • Genotype
  • Nomenclature
  • 13073-F
    tg/wt
    B6.CBA-Tg(Cdh5-cre/ERT2)1Rha
  • 13073-M
    tg/wt
    B6.CBA-Tg(Cdh5-cre/ERT2)1Rha
  • An inducible cre deleter under the control of the vascular endothelial cadherin (Cdh5(PAC)) promoter
  • Cre recombination is inducible via administration of tamoxifen
  • Useful for study of angiogenesis, atherosclerosis and neovascularization
  • Non-induced Cdh5(PAC)-CreERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Cdh5(PAC)-CreERT2 mice demonstrate high levels of recombinase-mediated gene deletion in vascular endothelial cells (95%+).

Origin:

The Cdh5(PAC)-CreERT2 Mouse was developed in the laboratory of Ralf Adams at the London Research Institute. The model was generated by microinjecting a transgene containing a genomic Cdh5(PAC) promoter fragment fused to a CreERT2 cDNA into B6xCBA F1 zygotes. Founder lines were backcrossed to C57BL/6 for at least five generations. Taconic received embryos from CRT in 2013.


Source:

Sponsor: Cancer Research Technology

Availability:

Limited quantities of breeders are available for purchase after execution of a license.

Color:

Black

Species:

Mouse

Initial Publication:

Sörensen I, Adams RH, Gossler A. (2009) DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. Blood. 113(22):5680-8.  



Access to this model requires execution of a Limited Breeding Agreement. Current Limited Breeding Agreement fees for this model are $2,500/year (€2000/year) for nonprofit users and $10,000/year (€8000) for for-profit users.

Purchase of line #13073 includes the right under the patents owned by Le Centre Européen de Recherche en Biologie et en Médecine ("CERBM") to perform inducible deletion (e.g. tamoxifen induction based deletion) using the CreER gene.